Fidelity Investments’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Fidelity Investments’s Portfolio CNCR Stock Details CNCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1	Closed	–	–	5010
2021 Q4	$0	Buy	+1	New	+$28	﹤0.01%	4395
2021 Q2	–	Sell	-1	Closed	–	–	4316
2021 Q1	$0	Buy	+1	New	+$33	﹤0.01%	4028
2020 Q3	–	Sell	-1	Closed	–	–	3711
2020 Q2	$0	Buy	+1	New	+$25	﹤0.01%	3647
2019 Q1	–	Sell	-1	Closed	–	–	3661
2018 Q4	$0	Buy	+1	New	+$21	﹤0.01%	3580

Other funds holding CNCR

BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Colony Group Boston, Massachusetts $6.66B AUM 18.65% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

APA

American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Fidelity Investments's CNCR Position: Q1 2022 in Review

Fidelity Investments sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q1 2022, closing a stake of 1 share.

Fidelity Investments first reported a position in CNCR in Q4 2018 and held it in 4 quarters. The position peaked at $0 in Q4 2021. 20 funds tracked by Wall St. Rank hold CNCR as of Q1 2022.

Fidelity Investments reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q1 2022 after selling out during the quarter.
Fidelity Investments sold 1 ETF Series Solutions Trust Range Cancer Therapeutics ETF share in Q1 2022.
Fidelity Investments first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q4 2018 and held it in 4 quarters.
Fidelity Investments's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $0 in Q4 2021.
20 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q1 2022.

Based on Fidelity Investments's 13F filing for Q1 2022, filed 13 May 2022.